Table 1.

Baseline demographic, immunovirological and ART history features of patients in therapeutic failure in Minas Gerais, Brazil: 2002–2012.

Characteristic	Percent (%)b												pb
	All years	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Analyzed sequences (N)	2115	39	77	171	183	279	120	291	284	252	175	244
Age (years)c	40.5 (33.4–47.6)a	35.6	38.6	38.3	40.4	39.6	36.9	39.6	42.6	42.5	41.3	43.2	<0.001
Sex male (N. %)	1311 (62.0)	74.4	75.3	69.0	65.0	63.8	60.8	63.2	57.4	56.3	59.4	58.6	<0.001
Number of ART regimens before genotyping	3 (2–4)a	3.0	3.0	2.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	2.0	0.055
Prior use of monotherapy with zidovudine (N. %)	40 (1.9)	5.1	7.8	5.8	1.6	4.3	5.0	0.3	0.0	0.0	0.0	0.0	<0.001
Prior use of dual therapy (N. %)	650 (30.7)	51.3	57.1	42.1	42.6	39.4	24.2	27.5	28.2	21.0	25.1	16.4	<0.001
Use of unboosted PI-based therapy (N. %)	1339 (63.3)	82.1	84.4	73.7	73.2	71.0	71.7	65.3	60.9	57.5	56.0	37.7	<0.001
Use of boosted PI-based therapy (N. %)	1079 (51.0)	38.5	36.4	36.3	41.5	39.4	45.0	59.5	59.2	58.7	55.4	60.7	<0.001
Prior use of NNRT (N. %)	1528 (72.3)	56.4	49.4	62.0	65.0	59.9	69.2	81.1	77.1	79.0	78.3	82.8	<0.001
Prior use of T20 (N. %)	48 (2.3)	0.0	0.0	0.0	0.0	0.4	0.8	7.9	2.5	4.0	1.7	1.2	<0.001
Prior use of RAL (N. %)	24 (1.1)	0.0	0.0	0.0	0.0	0.0	0.0	2.7	1.1	2.0	1.1	2.5	0.014
Prior use of ETR (N. %)	2 (0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.140
Baseline CD4+ T-cell count (cells/μL)c	226.0 (84–368)a	235.0	196.0	220.0	196.0	218.0	259.5	268.0	218.5	210.5	239.0	210.0	0.062
Baseline HIV-1 plasma viral loadc (log10 copies/mL)	4.3 (3.9–4.7)a	4.7	4.5	4.4	4.4	4.3	4.4	4.2	4.2	4.1	4.0	3.9	<0.001
Subtype (N.%)
B	1294 (61.2)	64.1	70.1	67.8	71.6	62.7	63.3	55.0	62.0	57.9	57.1	55.3	<0.001
F	463 (21.9)	17.9	20.8	22.8	19.1	24.4	20.8	24.1	18.3	19.4	24.6	24.2	0.647

^aValues: median (p25–p75).

^bCochrane–Armitage test for trends.

^cPearson correlation for trends.